{
  "nctId": "NCT03654131",
  "briefTitle": "Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver",
  "officialTitle": "Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver - a Randomized Phase II Trail",
  "protocolDocument": {
    "nctId": "NCT03654131",
    "filename": "Prot_002.pdf",
    "label": "Study Protocol",
    "date": "2019-04-16",
    "uploadDate": "2019-10-15T05:23",
    "size": 331789,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03654131/document/Prot_002.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 100,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-07-25",
    "completionDate": "2029-12-03",
    "primaryCompletionDate": "2027-12-03",
    "firstSubmitDate": "2018-08-27",
    "firstPostDate": "2018-08-31"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Colorectal cancer patients with oligo metastatic disease in the liver (1 to 3 tumors), and where metastases are found unsuitable for resection because of\n\n   1. non-resectability\n   2. small metastasis localized deep in the liver, where a parenchyma sparing intervention is preferred over an extensive resection\n   3. previous extensive liver surgery\n   4. comorbidity\n2. The multidisciplinary team should all agree that both percutaneous or open surgical MW-ablation and SBRT are safe as first treatment choice for the individual patient.\n3. Tumor sizes ≤4.0 cm\n4. Age \\> 18 years\n5. Signed informed consent\n\nExclusion Criteria:\n\n1. Previous radiotherapy to the liver\n2. Liver volume \\< 700 ml\n3. Another active cancer disease within the past 36 months\n4. Not able to understand written or oral protocol information",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Freedom from local lesion progression (analyzed on patient-level)",
        "description": "* Defined as the time from randomization to local progression\n* Censoring: death from any cause, last follow-up\n* No censoring on disease progression outside of the treated lesions\n* Local lesion progression is defined as \\>20% increase in the longest diameter and minimum 5 mm increase talking as reference the smallest longest diameter recorded since the treatment started in any of the treated lesions",
        "timeFrame": "3 years"
      }
    ],
    "secondary": [
      {
        "measure": "Overall survival",
        "description": "* Defined as the time from randomization to death from any cause\n* Censoring: last follow-up",
        "timeFrame": "3 years"
      },
      {
        "measure": "Freedom from local lesion progression (analyzed on lesion-level)",
        "description": "* Defined as the time from randomization to local progression\n* Censoring: death from any cause, last follow-up\n* No censoring on disease progression outside of the treated lesions\n* Local lesion progression is defined as \\>20% increase in the longest diameter and minimum 5 mm increase talking as reference the smallest longest diameter recorded since the treatment started in any of the treated lesions",
        "timeFrame": "3 years"
      },
      {
        "measure": "≥ grade 3 toxicity potentially associated with the treatment",
        "description": "* Defined as the time from randomization to first ≥ grade 3 toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0\n* Censoring: death from any cause, last follow-up",
        "timeFrame": "3 years"
      },
      {
        "measure": "Toxicity profile as descriptive statistics",
        "description": "Using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0",
        "timeFrame": "3 years"
      },
      {
        "measure": "Quality of life as descriptive statistics: EORTC QLQ-C30",
        "description": "Using EORTC QLQ-C30",
        "timeFrame": "3 years"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 49,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:54.637Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}